Univ.-Prof. Dr. med. Georg Heß

• Klinische und wissenschaftliche Schwerpunkte
• Publikationen (Auswahl)

Klinische und wissenschaftliche Schwerpunkte

• Klinische Schwerpunkte:
  Non-Hodgkin-Lymphome, Multiples Myelom, Chronische lymphatische Leukämie
   
• Wissenschaftliche Schwerpunkte:
  Minimale Resterkrankung, optimierte Therapie lymphatischer Neoplasien

Publikationen (Auswahl)

• Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S,  Liberati AM, Milpied N, Hess G, Stein H, Kalmus J, Marcus R. Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation. Blood, 2007, 2007-01-068056v1
• Heidel F and Lipka DB, von Auer C, Huber C, Scharrer I, Hess G. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007; 97, 2007,  228-33
• Hess G, Flohr T, Kolbe K, Bonn S, Schuler M, Derigs HG et al. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma. Ann Hematol. 2006
• Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B et al. Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study. Journal of Clinical Oncology 2005;23: 7583-93.
• Hess G, Flohr T, Huber C, Kolbe K, Derigs HG, Fischer T. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;31: 775-82.